华纳药厂：子公司磷霉素氨丁三醇原料药通过巴西GMP认证

Core Viewpoint - Warner Pharmaceuticals announced that its wholly-owned subsidiary, Chiral Pharmaceuticals, received a Good Manufacturing Practice (GMP) certification from Brazil's National Health Surveillance Agency for the active pharmaceutical ingredient fosfomycin trometamol, valid until January 19, 2028. This certification facilitates the entry of the product into the Brazilian market, enhancing international market expansion and competitiveness, although the international active pharmaceutical ingredient business faces uncertainties due to policy and market conditions [1]. Group 1 - The GMP certification is specifically for the active pharmaceutical ingredient fosfomycin trometamol [1] - The certification is valid until January 19, 2028 [1] - Fosfomycin trometamol is used in formulations for treating urinary tract infections [1] Group 2 - The certification creates conditions for the product's entry into the Brazilian market [1] - It is expected to aid in expanding international market presence and improving competitiveness [1] - The international active pharmaceutical ingredient business is subject to uncertainties influenced by policy and market environments [1]